EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD

Jennifer M Erichsen, Thomas C Register, Courtney Sutphen, Da Ma, Sarah A Gaussoin, Marc Rudolph, Melissa Rundle, James T Bateman, Samuel N Lockhart, Kiran K Solingapuram Sai, Christopher Whitlow, Suzanne Craft iD

Alzheimer's & Dementia · 2025-10 · 21 (10)

DOI: 10.1002/alz.70704 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.10.2025. Verfasst von Jennifer M Erichsen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carol…. Hauptthemen laut MEDLINE: Glucosides, Cognitive Dysfunction, Benzhydryl Compounds, Alzheimer Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Aptar Pharma, National Institute of Aging, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Agents targeting metabolic/vascular disorders are promising candidates to treat Alzheimer's disease (AD) and enhance safety and efficacy of other therapies. METHODS In a 2×2 factorial double‐blinded randomized trial, participants with mild cognitive impairment (MCI), early AD, or who were amyloid positive received intranasal insulin (INI; 40 IU q.i.d.), the sodium–glucose cotransporter‐2 inhibitor empagliflozin (10 mg q.d. oral tablet), both, or placebo for 4 weeks. The primary outcome was treatment‐related adverse events (TRAEs). Secondary outcomes included the modified Preclinical Alzheimer's Cognitive Composite‐5 (mPACC5), fluid biomarkers, cerebral blood flow (CBF), and fractional anisotropy (FA). RESULTS TRAEs were mild and similar for all groups. INI increased mPACC5, modulated FA and CBF, and reduced plasma glial fibrillary acidic protein. Empagliflozin lowered cerebrospinal fluid tau and modulated CBF. Both agents moderated immune/inflammatory/neurovascular markers. DISCUSSION INI and empagliflozin treatment was safe with promising effects on cognition, fluid, and imaging biomarkers. A longer and larger trial is needed to confirm these results. CLINICAL TRIAL REGISTRATION NCT05081219 Highlights Agents targeting metabolic or vascular disorders are promising candidates to prevent or treat Alzheimer's disease (AD). Intranasal insulin and empagliflozin were safe alone or in combination for mild cognitive impairment/AD. Insulin improved cognition and markers of inflammation and immune function. Empagliflozin reduced markers of vascular injury and neurodegeneration. A longer, larger trial is needed to validate these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesCognitive DysfunctionBenzhydryl CompoundsAlzheimer DiseaseInsulinSodium-Glucose Transporter 2 InhibitorsHumansMaleAdministration, IntranasalFemaleAgedDouble-Blind MethodBiomarkersTreatment Outcome

Stichwörter der Autor:innen

Alzheimer's diseaseempagliflozinimmune functioninsulinmetabolism

Substanzen

GlucosidesBenzhydryl CompoundsempagliflozinInsulinSodium-Glucose Transporter 2 InhibitorsBiomarkers

Autor:innen und Institutionen

  • Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

ORCID-Profile: Suzanne Craft

Förderung

  • Aptar Pharma
  • National Institute of Aging
  • NIA NIH HHS
  • Alzheimer's Association
  • Kulynych Cente for Memory and and Cognition
  • Kulynych Center for Memory and Cognition
  • National Institute on Aging

Zitieren

APA

Erichsen, J. M., Register, T. C., Sutphen, C., Ma, D., Gaussoin, S. A., Rudolph, M., Rundle, M., Bateman, J. T., Lockhart, S. N., Sai, K. K. S., Whitlow, C., & Craft, S. (2025). A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD. Alzheimer's & Dementia, 21(10). https://doi.org/10.1002/alz.70704

Vancouver

Erichsen JM, Register TC, Sutphen C, Ma D, Gaussoin SA, Rudolph M, et al. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD. Alzheimer's & Dementia. 2025;21(10). doi:10.1002/alz.70704

BibTeX
@article{Erichsen2025,
  author = {Erichsen, Jennifer M and Register, Thomas C and Sutphen, Courtney and Ma, Da and Gaussoin, Sarah A and Rudolph, Marc and Rundle, Melissa and Bateman, James T and Lockhart, Samuel N and Sai, Kiran K Solingapuram and Whitlow, Christopher and Craft, Suzanne},
  title = {A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {10},
  doi = {10.1002/alz.70704}
}
Kostenlos starten →